Viral and host factors related with histopathologyc activity in patients with chronic hepatitis B and moderate or intermittently elevated alanine aminotransferase levels

Revista Espanola de Enfermedades Digestivas

Volumn 102, Issue 9, 2010, Pages 519-525

  Molina Perez E ^a   Castroagudin J F ^a   Aguilera Guirao, A ^a   Otero Anton E ^a   Tome Martinez de Rituerto S ^a   Mera Calvino J ^a   Rodriguez Calvino J J ^a   Dominguez Munoz J E ^a  

^a University Hospital of Santiago de Compostela   (Spain)

Author keywords

Alanine aminotransferase; Chronic hepatitis B; DNA HBV; Genotype; HBV infection; Histological lesion; Liver biopsy

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; BIOLOGICAL MARKER; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; GENOTYPE; HEPATITIS B; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; SCORING SYSTEM; SERODIAGNOSIS; SEX DIFFERENCE; THROMBOCYTE COUNT; TREATMENT PLANNING; VIRUS LOAD;

EID: 78649561234     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082010000900002     Document Type: Article

References (27)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
2. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, et al. Occurrence of hepatocellular carcinoma and descompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995; 21: 77-82.
3. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008: 335-352.
4. Di Marco V, Lo Iacono O, Camma C, Vaccaro A, Giunta M, Martorana G, et al. The long-term course of chronic hepatitis B. Hepatology 1999; 30: 257-264.
5. European Association for the study of the liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B, J Hepatol 2009; 50: 227-242.
6. Lock AS, McMahon BJ; Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 857-861.
7. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6(12): 1315-1341.
8. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49: S45-S53.
9. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007; 47: 760-767.
10. Kumar M, Sarin SK, Hissar S, Pande C, Sakhuja P, Sharma BC, et al. Virologic and histologic features of chronic hepatitis b virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008; 134: 1376-1384.
11. Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 1998; 27: 1213-1219.
12. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-9.
13. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686.
14. Chen CJ, Yang HL, Su J, You SL, Lu SN, Huang GT, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
15. Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008; 48(Supl. 1): S2-19.
16. Papatheodoridis GV, Manesis EK, Manolakopoulos S, Elefsiniotis IS, Goulis J, Giannousis J, et al. Is there a meaningful serum hepatitis B virus DNA cuttof level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology 2008; 48: 1451-1459.
17. Sánchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodés J. Influence of hepatitis b genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002; 123: 1848-1856.
18. Miyakawa Y, Mikozami M. Classifying hepatitis B virus genotypes. Intervirology 2003; 46: 329-338.
19. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
20. Scheuer PJ. Classification of chronic viral hepatitis: a need for a reassessment. J Hepatol 1991; 13: 372-373.
21. Taylor BC, Yuan JM, Shamliyan TA, Shaukat A, Kane RL, Wilt TJ. Clinical outcomes in adults with chronic hepatitis b in association with patient and viral characteristics: a systematic review of evidence. Hepatology 2009; 49: S85-S95.
22. Huo TI, Wu ML, Hwang SJ, Lai CR, Lee PC, Tsay SH, et al. Factors predictive of liver cirrhosis in patients with chronic hepatitis B: a multivariate analysis in a longitudinal study. Eur J Gastroenterol Hepatol 2000; 12: 687-693.
23. Park BP, Park YN, Ahn SH, Lee KS, Chon CY, Moon YM, et al. Long-term outcome of chronic hepatitis B based on histological grade and stage. J Gastroenterol Hepatol 2007; 22: 383-388.
24. Chen CJ, Yang HI, Iloeje UH; For the REVEAL-HBV Study Group. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009; 49: S72-S84.
25. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al.; For the Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-174.
26. Kramvis A, Kew MC. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat 2005; 43: 411-417.
27. Kew MC, Kramvis A, Yu MC, Arakawa K, Hodkinson J. Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu- Speaking Sub-Saharan Africans. J Med Virol 2005; 75: 513-521.